Compound class
GLP-1 Peptides products are grouped here so buyers can compare related peptide options, verify current availability, and move into the catalog product pages that match their search intent.
Sort by
Retatrutide
$30.00
Retatrutide is a once-weekly triple GLP-1/GIP/glucagon receptor agonist — Phase 2 data showed 24.2% mean body weight reduction at 48 weeks, the highest result in obesity pharmacology Phase 2 trial history at publication.
Tirzepatide
$25.00
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class, with Phase III data showing 22.5% mean body weight reduction at 72 weeks, the highest performance in obesity pharmacology trial history at publication.
Semaglutide
$16.00
Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.
Cagri/Sema
$27.00
CagriSema is a fixed combination of cagrilintide (amylin analog) and semaglutide (GLP-1RA) studied in Phase 3 REDEFINE trials — 22.7% mean body weight reduction at 68 weeks, exceeding semaglutide-alone benchmarks.
Cagrilintide
$25.00
Cagrilintide is a long-acting amylin analog (~7-day half-life) developed for once-weekly combination dosing with semaglutide — the most clinically advanced amylin compound, with Phase 3 REDEFINE data published.